Seaport Therapeutics, Inc. SPTX
Seaport Therapeutics, Inc. (Nasdaq: SPTX) is a CNS/neurology/psychiatry drug developer. Its lead program, GlyphAllo (Glyph Allopregnanolone), is in Phase 2 for Major depressive disorder (MDD) with or without anxious distress. Its next catalyst on record is GlyphAllo: Phase 2b BUOY-1 topline data (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: GlyphAllo — Phase 2b BUOY-1 topline data (H1 2027). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| GlyphAllo (Glyph Allopregnanolone) | Major depressive disorder (MDD) with or without anxious distress | small molecule | Phase 2 |
| GlyphAgo (Glyph Agomelatine) | Generalized anxiety disorder (GAD) with sleep disturbance | small molecule | Phase 2 |
| Glyph2BLSD (Glyph 2-bromo-LSD) | Neuropsychiatric and headache disorders | small molecule | Pre-clinical |
Recent results and decisions
- Oct 1, 2026started Seaport dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance.
Dosed first patient in Phase 2a trial of GlyphAgo in patients with generalized anxiety disorder (GAD) and sleep disturbance.
Filing - started Seaport dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance.
Dosed first patient in Phase 2a trial of GlyphAgo in patients with generalized anxiety disorder (GAD) and sleep disturbance.
Filing - Sep 1, 2026positive GlyphAllo met its primary endpoint in a Phase 1 driving simulation trial, showing no impairment of next-morning driving performance compared to placebo.
The trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosing.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.